<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PROCYCLIDINE HYDROCHLORIDE</span><br/>(proe-sye'kli-deen)<br/><span class="topboxtradename">Kemadrin, </span><span class="topboxtradename">Procyclid <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">anticholinergic (parasympatholytic)</span>; <span class="classification">antimuscarinic</span>; <span class="classification">antispasmodic</span>; <span class="classification">antiparkinsonism agent</span><br/><b>Prototype: </b>Atropine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Centrally acting synthetic anticholinergic agent with actions similar to those of atropine. Selectively blocks muscarinic
         responses to acetylcholine (ACh), whether excitatory or inhibitory.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Diminishes the characteristic tremor of parkinsonism.</p>
<h1><a name="uses">Uses</a></h1>
<p>To relieve symptoms of parkinsonism syndrome (postencephalitic, arteriosclerotic, and idiopathic), and drug-induced extrapyramidal
         symptoms.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Angle-closure glaucoma. Safety during pregnancy (category C), lactation, or in children is not established.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypotension; mental disorders; tachycardia; prostatic hypertrophy.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Parkinsonism Symptoms</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 2.5 mg t.i.d. p.c., may be gradually increased to 5 mg t.i.d. if tolerated with an additional 5 mg h.s. (max: 4560 mg/d)<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span> Start with 2.5 mg 12 times/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Minimize adverse effects by administration of drug during or after meals.</li>
<li>Store at 15°30° C (59°86° F) in tightly closed containers unless otherwise directed.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Flushing of skin, decreased sweating, headache, lightheadedness, dizziness, feeling of muscle weakness. <span class="typehead">Special Senses:</span> Blurred vision, mydriasis, photophobia. <span class="typehead">CV:</span> Palpitation, tachycardia, <span class="speceff-common">hypotension.</span> <span class="typehead">GI:</span> <span class="speceff-common">Dry mouth,</span> nausea, vomiting, epigastric distress, constipation, <span class="speceff-life">paralytic ileus</span>, acute suppurative parotitis. <span class="typehead">Urogenital:</span> Urinary retention. <span class="typehead">Skin:</span> Skin eruptions (occasionally). <span class="typehead">CNS:</span> Mental confusion, psychotic-like symptoms. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Additive adverse effects with <span class="classification">anticholinergic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 3540 min. <span class="typehead">Duration:</span> 46 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor heart rate and rhythm and BP. Report palpitations, tachycardia, paradoxical bradycardia, or decreasing BP. Dosage
            adjustment or discontinuation of drug may be indicated.
         </li>
<li>Monitor therapeutic effectiveness. Generally more effective in controlling rigidity than tremors. Tremors may temporarily
            appear to be exaggerated as rigidity is relieved, especially in patients with severe spasticity.
         </li>
<li>Observe for and report symptoms of mental confusion, disorientation, agitation, and psychotic-like symptoms, particularly
            in older adult patients who have low BP, to physician.
         </li>
<li>Check for constipation and abdominal distention and provide information for preventing constipation.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Void before taking drug if urinary hesitancy or retention is a problem.</li>
<li>Avoid potentially hazardous activities until response to drug is known because drug may cause blurred vision and dizziness.</li>
<li>Relieve dry mouth by rinsing frequently with water, chewing sugarless gum or sucking hard candy, or increasing noncaloric
            fluid intake. If these measures fail, a saliva substitute, available OTC, may help (e.g., Orex, Xero-Lube).
         </li>
<li>Avoid alcohol and do not to take other CNS depressants unless otherwise advised by physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>